This was the second candidate - BNT162b2 - tested by Pfizer-BioNTech. A total of 30,000 Americans are registered for the trials, but only a portion of them were involved in phase one of the clinical tests. The vaccine succeeded in inducing immunity against COVID-19, while showing no adverse reaction or side-effects.